Following a CHF 2.4 million seed round, Aseptuva progressed to preclinical validation

Last year Swiss-UK Medtech startup Aseptuva raised CHF 2.4 million from prominent healthcare entrepreneurs and investors. The financing has enabled Aseptuva to progress from early prototyping to preclinical validation in Europe.
Read the full article on Startupticker

zurück

We use cookies to make our website user-friendly and reliable; this includes measuring performance and reach. Further information can be found in our Privacy Policy.